February 13th 2023
Joyce O’Shaughnessy, MD, starts a conversation on which patients with HER2+ early breast cancer are the best candidates for extended adjuvant neratinib therapy.
A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.
February 7th 2023
The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.
A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.
January 30th 2023
The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.
Debu Tripathy, MD, details when he utilizes a treatment de-escalation approach in his patients with HER2+ early breast cancer.
January 20th 2023
A review of the standard of care regimens for the preoperative or neoadjuvant treatment of HER2+ early breast cancer.
Virginia Borges, MD, explains how common HER2+ early breast cancer is and the goals of treatment for patients.